Abevmy 100 Mg Injection (Bevacizumab)
$930.00 – $2,613.19Price range: $930.00 through $2,613.19RxRequired
-
United States dollar ($) - USD
-
Euro (€) - EUR
-
Canadian dollar ($) - CAD
| Pack Size | Price | Unit Price | Quantity | |
|---|---|---|---|---|
| 2 Injection | $930.00 | $465.00 / injection | ||
| 4 Injection | $1,798.53 | $449.63 / injection | ||
| 6 Injection | $2,613.19 | $435.53 / injection |
Add $199.00 to cart and get free shipping!
About Abevmy 100 Mg Injection (Bevacizumab)
Medicine information
- Active ingredient
- Bevacizumab
- Indication
- Treatment of certain adult cancers, including metastatic colorectal cancer, metastatic breast cancer, unresectable advanced/metastatic/recurrent non-squamous non-small cell lung cancer, advanced or metastatic renal cell cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and persistent, recurrent, or metastatic cervical cancer. Abevmy is generally used with specified chemotherapy or other anticancer medicines depending on the indication; approved combinations vary by cancer type and jurisdiction. Rwanda FDA
- Manufacturer
- Biocon Limited, manufactured for Mylan Pharmaceuticals Private Limited, India. Rwanda FDA
- Packaging
- Pack of 1 single-use vial containing 4 mL of 25 mg/mL bevacizumab solution, equivalent to 100 mg bevacizumab. The solution is supplied in a USP Type I glass vial. Rwanda FDA
- Strength
- 100 mg
- Dosage form
- Concentrate for solution for infusion
- Route
- Intravenous infusion
Medicine overview
Abevmy 100 mg is an anticancer biological medicine containing bevacizumab, a recombinant humanised monoclonal antibody. It is a biosimilar bevacizumab product supplied as a 25 mg/mL concentrate, with 100 mg in each 4 mL vial. Abevmy is used in the treatment of several advanced or metastatic cancers, often together with chemotherapy or another anticancer medicine. It must be diluted and administered as an intravenous infusion by healthcare professionals experienced in cancer treatment.
Rwanda FDA
What it is used for
Abevmy is used as part of treatment for selected adult cancers, including metastatic colorectal and breast cancer, non-squamous non-small cell lung cancer, advanced or metastatic renal cell cancer, ovarian, fallopian tube and primary peritoneal cancers, and persistent, recurrent or metastatic cervical cancer. The accompanying medicines and treatment setting differ between indications, so Abevmy is used according to an oncology treatment protocol rather than as a general-purpose anticancer injection.
Rwanda FDA
How it works
Bevacizumab binds to vascular endothelial growth factor, or VEGF, a protein involved in forming new blood vessels. By neutralising VEGF, it prevents VEGF from activating receptors on blood-vessel-forming cells. This reduces the development of new blood vessels supplying a tumour and can limit the tumour's access to oxygen and nutrients. Through this anti-angiogenic effect, Abevmy can slow tumour growth when used in an appropriate cancer treatment regimen.
Biocon Biologics
How it is taken
Abevmy is administered only by intravenous infusion under the supervision of a physician experienced with antineoplastic medicines. The required amount is diluted with 0.9% sodium chloride solution; it must not be given as an intravenous push or bolus or mixed with glucose solutions. The first infusion is normally given over 90 minutes. If tolerated, the second may be given over 60 minutes and later infusions over 30 minutes. The dose and treatment interval depend on the cancer and treatment regimen.
Rwanda FDA
Important warnings
Do not use Abevmy in patients with hypersensitivity to bevacizumab, its excipients, Chinese hamster ovary cell products, or other recombinant human or humanised antibodies; pregnancy is also listed as a contraindication in the product information. Major risks include gastrointestinal perforation and fistula formation, serious or fatal bleeding, impaired wound healing, severe hypertension, arterial or venous blood clots, proteinuria and nephrotic syndrome, posterior reversible encephalopathy syndrome (PRES), infusion or hypersensitivity reactions, congestive heart failure, and rare necrotising fasciitis. Blood pressure and urine protein require monitoring. Treatment around major surgery requires careful timing because bevacizumab can interfere with wound healing. Urgent assessment is needed for severe abdominal pain, major bleeding or coughing up blood, chest pain, sudden neurological symptoms, seizures, severe shortness of breath, or signs of a serious allergic reaction.
Side effects and monitoring
Common or very common effects reported with bevacizumab include high blood pressure, fatigue or weakness, diarrhoea, abdominal pain, nausea, headache and reduced blood-cell counts; some effects also reflect the chemotherapy used with it. Serious reactions include gastrointestinal perforation or fistula, severe haemorrhage, arterial or venous thromboembolism, severe hypertension, PRES, nephrotic syndrome, serious infection, wound-healing complications and infusion reactions. Blood pressure should be checked regularly, urine should be monitored for protein, and blood counts may be monitored according to the accompanying oncology regimen. Seek prompt medical attention for major bleeding, severe or persistent abdominal pain, breathing difficulty, chest pain, sudden weakness or neurological changes, seizures, or severe infusion/allergic symptoms.
Pregnancy
Abevmy is contraindicated during pregnancy because inhibition of VEGF-dependent blood-vessel development may harm the fetus. Women of reproductive potential should use effective contraception during treatment and for 6 months after the final dose.
Rwanda FDA
Breastfeeding
Breastfeeding should be discontinued during treatment with Abevmy and avoided for at least 6 months after the final dose. It is not known whether bevacizumab is excreted in human milk, and harmful effects on infant growth and development cannot be excluded.
Rwanda FDA
Food and drink
No clinically established food interaction has been identified in the product information. Because Abevmy is administered intravenously, food does not determine its absorption.
Biocon Biologics
Storage
Store unopened vials refrigerated at 2°C to 8°C. Do not freeze. Keep the vial in its outer carton to protect it from light. Abevmy contains no antimicrobial preservative and is intended for single use; unused product should be discarded according to applicable requirements.
Rwanda FDA
Frequently asked questions
Is Abevmy the same medicine as Avastin?
Abevmy contains bevacizumab and is a biosimilar to the reference bevacizumab medicine Avastin. Biosimilars are highly similar biological medicines with no clinically meaningful differences in approved quality, safety and effectiveness, but the exact approved indications can differ by country.
How long does an Abevmy infusion take?
The first infusion is normally given over 90 minutes. If it is well tolerated, the second may be given over 60 minutes and later infusions over 30 minutes.
Why does my blood pressure need checking during bevacizumab treatment?
Bevacizumab can cause or worsen high blood pressure, sometimes severely. Blood pressure is therefore monitored during treatment so clinically important increases can be detected and managed.
Why is urine tested while I am receiving Abevmy?
Bevacizumab can cause protein to leak into the urine. Urine-protein monitoring helps identify this effect, including the uncommon but serious complication nephrotic syndrome.
Can Abevmy affect surgery or wound healing?
Yes. Bevacizumab can delay wound healing and has been associated with serious wound complications, so treatment must be coordinated carefully around major surgery by the oncology team.
Is fatigue common after bevacizumab infusions?
Yes. Fatigue or weakness is among the commonly reported effects of bevacizumab treatment, although symptoms can also come from the cancer itself or other medicines given at the same time.
What symptoms during Abevmy treatment need urgent medical attention?
Seek urgent medical care for severe abdominal pain, significant or persistent bleeding, coughing up blood, chest pain, sudden neurological symptoms, seizures, severe breathing difficulty, or signs of a serious infusion or allergic reaction. These may indicate uncommon but potentially serious complications.
Can Abevmy be used during pregnancy or breastfeeding?
No during pregnancy, and breastfeeding should be stopped during treatment. The product information advises avoiding breastfeeding for at least 6 months after the final dose and using effective contraception during treatment and for 6 months afterward.
Is Abevmy given as a quick injection into a vein?
No. Abevmy must be diluted and administered as an intravenous infusion; it must not be given as an intravenous push or bolus.
Medical information notice: This information does not replace advice from a qualified healthcare professional. Use prescription medicine only as directed by the prescriber and the approved product information.
| Active Ingredients | Bevacizumab |
|---|---|
| Manufacturer | Mylan Pharmaceuticals Pvt Ltd |
| Packaging | Qty |
| strength | 100mg |
| Delivery Time | 6 To 15 days |

Reviews
There are no reviews yet.